Table 1.
List of COG early-phase trials analyzed
| COG Study |
Phase | Treatment | Timing of Response Assessment* After: |
Days from study enrollment to first response assessment |
Number of patients analyzed* |
|---|---|---|---|---|---|
| ADVL0211 | 1 | G3139, Cytotoxic Chemotherapy | cycle 1,3,5,7,… | 21 | 5 |
| ADVL0212 | 1 | Depsipeptide | course 1 and 2 | 28 | 1 |
| ADVL0214 | 1 | Tarceva, Tarceva + Temozolomide | cycle 2,4,6,8,,… | 56 | 2 |
| ADVL0215 | 1 | Decitabine, Doxorubicin, Cyclophosphamide | each course | 28 | 12 |
| ADVL0314 | 1 | Bevacizumab | cycle 1,3,5,7,… | 28 | 2 |
| ADVL0316 | 1 | 17-AAG | course 1 | 21 | 1 |
| ADVL0319 | 1 | Lenalidomide | cycle 1,3,5,7,… | 28 | 1 |
| ADVL0414 | 1 | Temozolomide, Irinotecan, Vincristine | course 2,4,8,12,16,… | 42 | 2 |
| ADVL0415 | 1 | Oxaliplatin, Irinotecan | cycle 1,3,5,7,… | 21 | 1 |
| ADVL0416 | 1 | SAHA, 13 Cis-Retinoic Acid | cycle 1,3,5,7,… | 28 | 5 |
| ADVL0516 | 1 | Dasatinib | cycle 1,3,5,7,… | 28 | 1 |
| ADVL0517 | 1 | Ispinesib | cycle 1,3,5,7,… | 28 | 1 |
| ADVL0714 | 1 | VEGF Trap | cycle 2,6,10,14,,… | 28 | 1 |
| ADVL0813 | 1 | IMC-A12, (Temsirolimus | cycle 1,3,5,7,… | 28 | 2 |
| ADVL0815 | 1 | Pazopanib | cycle 1,2,4,6,8,… | 28 | 1 |
| ADVL0816 | 1 | Obatoclax/Vincristine/Doxorubicin/Dexrazoxane | cycle 1,3,5,7,… | 28 | 3 |
| ADVL0911 | 1 | Seneca Valley Virus | 4 weeks after 2nd infusion, then Weeks 8,16,28,40,52,… | 56 | 2 |
| ADVL0916 | 1 | Vorinostat, Bortezomib | each cycle | 21 | 3 |
| ADVL0918 | 1 | Temsirolimus, Irinotecan, Temozolomide | cycle 2,4,6,9,12,… | 42 | 13 |
| ADVL1013 | 1 | MK-2206 | cycle 1,3,5,8,11,… | 28 | 3 |
| ADVL1014 | 1 | REOLYSIN | cycle 1,3,5,8,11,… | 28 | 1 |
| ADVL1111 | 1 | c-Met Inhibitor, Tivantinib | cycle 1,3,5,8,11,… | 28 | 2 |
| ADVL1112 | 1 | Imetelstat | cycle 1,3,5,8,11,… | 21 | 4 |
| ADVL0413 | 1/2 | Sorafenib | cycle 2,4,6,8,,… | 56 | 1 |
| ADVL0812 | 1/2 | MLN8237 | cycle 1,3,5,7,9,… | 21 | 16 |
| ADVL0912 | 1/2 | PF-02341066 | cycle 1,3,5,7,10,13,… | 28 | 24 |
| ANBL0321 | 2 | Fenretinide | courses 2,4,7,11,15,19,23 | 42 | 59 |
| ANBL0322 | 2 | hu14.18-IL2 | 2 monthly courses | 56 | 35 |
| ANBL0421 | 2 | Irinotecan, Temozolomide | courses 3 and 6 | 63 | 55 |
| ANBL0621 | 2 | ABT-751 | cycle 2,4 6,8,10,14,… | 42 | 71 |
| ADVL0421 | 2 | Oxaliplatin | course 2,4,6,8,… | 42 | 10 |
| ADVL0524 | 2 | Ixabepilone | cycles 1,3,5,7,… | 21 | 9 |
| ADVL0525 | 2 | Pemetrexed | cycle 1,3,5,7,… | 21 | 4 |
| ADVL0821 | 2 | IMC-A12 | cycle 1,2,3,5,7,… | 28 | 20 |
| ADVL0122 | 2 | Gleevec | course 2,4,6,9,12,15,… | 56 | 10 |
*
This is the subset of patients enrolled on the trial who met the eligibility criteria for this analysis.